Akari Therapeutics (AKTX) Times Interest Earned (2014 - 2026)
Akari Therapeutics' (AKTX) quarterly Times Interest Earned came in at -$258.33 in Q1 2026, down 303.06% year-on-year from $127.21 in Q1 2025, and down 6696.42% quarter-over-quarter from -$3.8 in Q4 2025.
Akari Therapeutics (AKTX) Times Interest Earned (2014 - 2026) Analysis & Trends
Akari Therapeutics has disclosed Times Interest Earned across 5 years of filings, most recently posting -$258.33 for Q1 2026.
- Times Interest Earned for Q1 2026 came in at -$258.33, down 303.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$27.3 (down 511.09% YoY), and the FY2025 annual result was -$18.2, up 99.75% from the prior year.
- Times Interest Earned came in at -$258.33 for Q1 2026 at Akari Therapeutics, down from -$3.8 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$3.8 in Q4 2025 to a low of -$258.33 in Q1 2026.
- The 3-year median for Times Interest Earned is -$61.79 (2025), against an average of -$80.28.
- Across the five-year window, Times Interest Earned soared 57.29% in 2025 and tumbled 303.06% in 2026, its largest moves.
- Akari Therapeutics' Times Interest Earned stood at -$4.0 in 2024, then climbed by 4.94% to -$3.8 in 2025, then slumped by 6696.42% to -$258.33 in 2026.
- The last three Times Interest Earned figures came in at -$258.33 (Q1 2026), -$3.8 (Q4 2025), and -$61.19 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 49.84 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -258.33 |
| Dec 31, 2025 | -3.80 |
| Sep 30, 2025 | -61.19 |
| Jun 30, 2025 | -62.38 |
| Mar 31, 2025 | -64.09 |
| Dec 31, 2024 | -4.00 |
| Sep 30, 2024 | -42.42 |
| Jun 30, 2024 | -146.06 |
| Dec 31, 2015 | 721.17 |
| Sep 30, 2015 | -7.64 |
| Mar 31, 2015 | -363.18 |
| Dec 31, 2014 | 523.51 |
| Sep 30, 2014 | -75.65 |